Antiviral gel as gel based on human leukocyte interferon
FIELD: medicine, chemical-pharmaceutical industry.
SUBSTANCE: invention relates to an antiviral agent as gel. Agent comprises human leukocyte interferon and 2-% solution of styrene copolymer and maleic anhydride as gel-forming base in the following ratio of the agent components, in 1 g of the agent: concentrated interferon, 5000-10000 IU; nipagin, 0.002-0.004 g and a base, the balance. Proposed agent possesses high activity, nontoxic and possesses antiviral, immunomodulating, anti-inflammatory and regenerative effects and can be used in ophthalmology, dermatology, gynecology and surgery for topical using and in treatment of viral diseases.
EFFECT: valuable medicinal properties of agent.
2 tbl, 2 ex
The invention relates to medicine, biotechnology and relates to dosage forms containing the human leukocyte interferon (IFN) and can be used in ophthalmology, dermatology, gynecology, surgery for local use.
Interferon is an important part of the adaptive mechanisms of the organism while maintaining its homeostasis. It is shown that the biological activity of IFN directed against all known RNA - and DNA-containing viruses, bacteria .
Given the experience gained in recent years from the use of drugs interferon, there is a need to improve their effectiveness through the creation of dosage forms for local use.
Known ointment with human leukocyte interferon "Interon containing human leukocyte interferon purified and dipilou basis, including vaseline and surface-active substances (SAS) . Vaseline as the basis of poorly miscible with water, medicinal substances of vaseline practically not absorbed, so based ointment vaseline used for surface action. They are on the skin surface to form a dense film, breaking the gas exchange, possible allergic reactions. Furthermore, the hydrophobic base makes contact with mucous membranes, so the application of ointments with fatty bases on themucous does not give a high effect. Hydrophilic base promotes good absorption, which is very convenient for frequent use.
Known interferon gel kit including lyophilized interferon and Poloxamer gel . This invention uses a sophisticated packing material. Components are Packed in a bottle with a removable lid and a flexible reservoir separately. The components are mixed immediately before use, which increases the number of additional technological methods performed by the consumer. Used import gelling (Poloxamer), details of which are absent in the State register of medicines of Russia. In our invention are domestic gelling.
Known "Antiviral agent in ointment form - based interferon-alpha 2", containing recombinant interferon α on hydrogel-based hydrate of aluminum oxide with addition of polyvinyl alcohol .
Known antiviral agent-based recombinant interferon in the form of an ointment, gel, suppository, cream, liniment. The basis of the gel forms an alloy of polyethylene oxide-400 and polyethylene oxide-4000 with the addition of a solution of the stabilizer of nipagina and polyvinylpyrrolidone, as well as antioxidant from Trylon B and butylacetyl. Add dimethylsulfoxide .
Known l the drug gel with recombinant interferon and vitamin E, contains additional methionine, benzoic acid, citric acid, albumin human serum, ethyl alcohol, glycerin and others .
Known Pharmaceutical composition for the treatment and prevention of genital herpes, chronic papillomas virus infection and cervical cancer prevention (options)". The gel has the following composition: interferon - 50000-500000 ME in ml, serum albumin 1-2 mg/ml, E - aminocaproic acid 0.05 to 0.15 g/ml, Riboflavin - 0.04-0.06 g/ml, carboxymethylcellulose - 8.0 g, glycerol - 20,0 g, a PBS buffer to 200 ml . This drug is closest to the invention entity and selected as a prototype.
Recombinant interferons, being the products of one of the reconstructed gene, always one component that determines the potential for their therapeutic activity. The disadvantage of the use of drugs based on recombinant interferon - a chance to generate neutralizing protivovetrovyh antibodies, as well as potentiation of various complications . Natural interferon in contrast to recombinant is a natural product and contains the whole range of cytokines produced in the process of interferonogenesis in their natural ratio, it has no antigenic properties and does not cause sensitization by prolonged and mnogoe the nom introduction.
Object of the invention is the creation of new medicines in the form of a gel containing human leukocyte interferon with prolonged antiviral, immunomodulatory, antibacterial, anti-inflammatory and regenerative effect on the skin, does not cause sensitization by prolonged and repeated.
The technical result - the reduction of terms of treatment of viral lesions of the skin and mucous membranes. The technical result is good fixation and a uniform distribution in the tear fluid, does not violate the refraction in the eye gel.
This object is achieved in that the inventive gel for local application in the treatment of viral lesions of the skin and mucous contains interferon human leukocyte gel agent is a copolymer of styrene with maleic anhydride (SMA) in the following ratio of components in 1 g of a mixture of: concentrated interferon - 5000-10000 ME; preservative 0,002-0,004 g; 2%aqueous solution of a copolymer of styrene with maleic anhydride - rest.
SMA - redkosty swollen polymer does not have a local irritant to skin and mucous membranes of the eye (THE 6-01-02274010913-01). The appearance of a 2%aqueous solution of SMA is a clear or slightly cloudy gel. A copolymer of styrene with maleic anhydride know the ten as a tool for the treatment of herpetic keratitis .
Interferon-based gels, SSMA have a total double antiviral effect due to CSMA and interferon.
Natural interferon is a natural product and contains the whole range of cytokines produced in the process of interferonogenesis in their natural ratio, it has no antigenic properties and does not cause sensitization by prolonged and repeated.
The local application of human leukocyte interferon activated local cellular and humoral immune mechanisms, significantly increases the level of natural resistance, normal biocenosis. Regenerative effect of the drug due to activation of interferon local immunological mechanisms.
Examples preparation of a gel.
Example 1. SMA 2 g dissolved in 70 ml of water for injection, leave to swell for 1 hour, sterile fluid steam, add the concentrated interferon activity 30000-40000 ME to a concentration of 5,000 IU in 1 g of the resulting gel. Add 0.2 g of nipagin. The volume was adjusted to 100 ml with water for injection.
Example 2. SMA 2 g dissolved in 70 ml of water for injection, leave to swell for 1 hour, sterile fluid steam, add the concentrated interferon activity 30000-40000 ME to a concentration of 10000 ME in 1 g of the resulting gel. Add 0.4 g mipagi the and. The volume was adjusted to 100 ml with water for injection.
Obtained according to the invention, the gel used for the treatment of experimental herpetic keratitis rabbits. This model is convenient and informative as they can be reproduced, gives clear results of therapeutic efficacy, correlated with antiviral activity of the test drug. Used rabbits breed "Chinchilla" weighing 2.0 to 2.5 kg Experiments were performed on 6 groups of animals (3 rabbits - 6 eyes in each group). The first group consisted of untreated experimental animals (control), group II - treated with a solution of interferon activity of 10,000 IU/ml by instillation into the conjunctival cavity, the third group received the inventive gel containing 5000 IU/ml of interferon, the fourth group received the inventive gel containing 10,000 IU/ml of interferon, the fifth group received gel SMA and the sixth group received 3% ointment Zovirax (acyclovir, 9-(2-Hydroxy)ethoxymethylene; UK, Glaxo Smith Kline). Before infection with both eyes were anestesiologi 0.5% solution dikaina by instillation into the conjunctival cavity. The injection needle was applied surface linear notches (in the layers of the corneal epithelium) in the form of 3 mutually perpendicular strips. For infection used the culture fluid containing the virus is simple the first herpes simplex virus (HSV), strain L2 with an activity of 103,5Tcco / 0.1 ml in the culture of Vero cells. Clinical biomicroscopic study of the development of the clinical picture of herpes keratitis was performed using a slit lamp SL-5 KOWA (Japan).
To determine the degree of severity of the clinical picture in experimental animals, we developed a points system (table 1), based on biomicroscopic evaluation pattern of the anterior eye, the affected HSV. The results of the study were evaluated according to the degree of severity of experimental herpetic keratitis in points. Comparative evaluation of therapeutic activity of the inventive gel are presented in table 2.
Treatment of animals was performed at 24 hours after infection of the cornea of the rabbit HSV daily 3 times a day: in the conjunctival cavity was instillirovti 1-2 drops of interferon or laid declare gel or base or ointment Zovirax.
therapeutic effectiveness of the proposed gel of examples 1 and 2 were characterized by lower severity of clinical manifestations of herpetic keratoconjunctivitis and uveitis. So, when using the inventive gel severity of experimental herpetic lesions was evaluated in the range from 1.23±of 0.1 to 1.3±0.1 points, whereas in the control of 1.85±0.2 and in the group of animals treated with SMA 1,45±0,1 BA is La.
The comparative evaluation of therapeutic efficacy of the compounds under investigation by the severity of the clinical course of herpetic keratitis in 5 days found that in this period after infection, the inventive gel possessed anti-herpes activity compared to control and the basis (p<0,05) table. . Developed gels were not lost on the biological activity of the drug "Zovirax".
Sources of information
1. Interferon status, preparations of interferon in the treatment and prevention of infectious diseases and rehabilitation. Under. edit NSW, Gennady Onishchenko, Whaleskin etc. / Moscow, 2005. - 767 S.
2. RU # 2141819 C1 6, A61K 9/06. 1999.11.27.
3. US No. 4469228.
4. RU # 2159609 C2, AC 9/06, 38/21. 27.11.2000.
5. RU # S 7, AC 38/21. 2000.06.10.
6. RU # 2184564 C2 7, AC 38/21. 2002.07.10.
7. RU # 2180593 C1 7, AC 38/19, AK 38/21. 2002.03.20
8. Volkova L.V. "Natural α-interferon and anti-bacterial peptide complex: production technology, new dosage forms, evaluation" / author. Diss. MD, Perm, 2004. - 41 S.
9. RU # 2135187 C1, A61K 31/765. 1999.08.27.
|System ball assess the severity of herpetic lesions of the retina of rabbits|
|Shell eyes||Clinical and biological picture herpete the definition of defeat||Points|
|The conditions||Not detected||0|
|Moderate hyperemia, infiltration of the conjunctiva||1|
|Marked hyperemia, infiltration, moderately detachable||2|
|Marked hyperemia, infiltration, abundantly detachable||3|
|The cornea||Not impressed||0|
|Single point star-shaped infiltrates||1|
|Infiltration over and around cuts||1,5|
|Infiltration optical zone 1/3 corneal ulceration of the epithelium in length||2,5|
|Infiltration 1/2 of the entire cornea, ulceration across the cornea||3,0|
|Neovasculature take 1/2 square||2|
|The newly formed vessels occupy the entire iris, swelling of the iris||3|
|The newly formed vessels occupy the entire iris, swelling of the iris, posterior synechia||4|
|Comparative evaluation of therapeutic activity of the inventive gel in experimental herpetic lesions of the eyes of rabbits|
|№ p/p||The group of experimental animals||The severity of herpes of the eye|
|3||The inventive gel according to example No. 1||1,3±0,1|
|4||The inventive gel according to example No. 2||1,23±0,1|
Antiviral agent in the form of a gel comprising an interferon and a base, characterized in that it contains a leukocyte interferon human, as the basis contains a copolymer of styrene with maleic anhydride in the following ratio of components in 1 g of a mixture of: interferon concentrated 5000-10000 ME, nipagin 0,002-0,004 g, 2%solution of a copolymer of styrene with maleic anhydride - rest.
FIELD: medicine, pharmacology.
SUBSTANCE: invention relates to a medicinal agent used in treatment of warts. Proposed agent contains an active compound chosen from isopropyl laurate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, ethyl myristate, propyl myristate, butyl myristate and/or ethyl oleate and at least a mixture containing (-)-epicatechol, (-)-epicatechol gallate, (-)-epigallocatechol, (-)-epigallocatechol gallate, (+)-gallocatechol and (-)-gallocatechol gallate possessing the enhanced effectiveness.
EFFECT: valuable medicinal properties of drug.
7 cl, 2 ex
FIELD: synthesis of biologically active compounds.
SUBSTANCE: invention provides novel urea-substituted imidazoquinoline ethers depicted by general formula I: (1), in which X represents -CHR5- or -CHR5-alkyl group; R1 is selected from radicals: -R4-NR8-CR3-NR5-Z-R6-Alk, -R4-NR8-CR3-NR5-Z-R6-Ph, -R4-NR8-CR3-NR5-Z-R6-furanyl, -R4-NR8-CR3-NR5R-7, phenyl being optionally substituted by one or more substituents selected from methyl, methoxy, methylthio, cyano, hydrogen, dimethylamino, and acetyl; R2 is selected from hydrogen, alkyl, and alkyl-Y-alkyl; R3 represents =O or =S; R4 represents alkyl optionally substituted by one or several O-groups; each of R5 represents C1-C10-alkyl; R6 represents ordinary bond or alkyl; R7 forms cycle together with R5; R4 represents hydrogen, C1-C10-alkyl, or forms morpholine ring together with R8; Y represents -O-; Z ordinary bond, -CO-, or -SO2-; n=0; each of R is independently selected from C1-C10-alkyl, C1-C10-alkoxy, hydroxy, halogen, and trifluoromethyl; or pharmaceutically acceptable salt of forgoing compounds. Described are further compounds of general formula II, intermediates of compounds of general formulae III and IV, pharmaceutical compositions based on compounds I and II, which are immunomodulators for synthesis of cytokines based on compounds I and II, methods of treating viral diseases utilizing compounds I and II, and methods of treating tumor diseases utilizing compounds I and II.
EFFECT: expanded synthetic possibilities in quinoline series and increased choice of therapeutically useful compounds.
25 cl, 4 tbl, 44 ex
FIELD: medicine, immunology.
SUBSTANCE: the present innovation deals with specific prophylaxis of smallpox and viral hepatitis B. The kit contains two tablets each contains stabilizing additives, a filler and lyophilized alive viral material worked out based upon recombinant VOV strain at typical VOV properties expressing proteins preS2-S and HBs virus of hepatitis B virus, the first immunizing dosage corresponds to minimal quantity of viral material being sufficient to obtain weak immune response in the body in case of insignificant at insignificant reactogenicity, and immunizing dosage of the second - maximal quantity of viral material that causes pronounced and prolong immune response in the body at no negative side action. The technique of applying the kit of bivaccine tablets, first, one should use the 1st tablet at minimal dosage of bivaccine, as for the 2nd tablet - with maximal dosage of bivaccine it should be taken till the moment of developing humoral answer (in 7-14 d) after injecting the 1st tablet at minimal immunizing dosage of bivaccine. The innovation enables to create stable immunity.
EFFECT: higher efficiency.
4 cl, 5 ex, 6 tbl
FIELD: veterinary science, virology, biotechnology.
SUBSTANCE: the suggested vaccine contains the suspension of avirulent and purified antigenic material out of the strain N 101 of cattle rotavirus (Research Institute of Animal Protection) obtained in mono-layer culture cells MDBK or SPEV at accumulation degree being 106 viral particles/ml, not less and activity in IEA being 5.0 log2, not less, and target additives: aluminum hydroxide and saponin in efficient ratios. The strain is deposited in collection of FGU VGNKI under registration number - a culture strain N 101 Research Institute of Animal Protection-DEP. The suggested vaccine is highly immunogenic, safe and areactogenic, it is capable to protect cattle stock against epizootic agent of rotaviral infection circulating in Russian territory.
EFFECT: higher efficiency.
14 cl, 9 ex, 10 tbl
FIELD: medicine, biology.
SUBSTANCE: the present innovation deals with the technology for manufacturing the series of preparations being of immunoregulating action and could be applied for manufacturing vaccines and preparations for the purposes mentioned. It is necessary to dissolve 3000 g sugar in bidistilled water up to saturated syrup to sterilize it due to boiling followed by cooling it up to about 45-50°C, then one should add as a basis 30 g protein bile fraction of two ad more even-toes animals dissolved in 200 g bidistilled water, the mixture should be thoroughly mixed to dry it up to the end in oven drier at 45-50°C, then the mixture should be ground to sterilize the powder obtained that contains a target product with quartz irradiation to be packed into gelatinous capsules NN 1-3 at 0.5-1.5 g dosage. The innovation provides the development of reliable, economically profitable technology for manufacturing native preparations of immunoregulating action that enables to shorten terms of therapy, prolong terms of remission, achieve complete recovery in case of viral diseases and intoxications and decrease lethality percentage in case of the diseases mentioned.
EFFECT: higher efficiency.
FIELD: medicine, pharmacology, bioorganic chemistry, pharmacy.
SUBSTANCE: invention relates to the effective using amount of β-L-2'-deoxynucleoside of the formula (I) or (II) used in manufacturing a medicinal agent used in treatment of hepatitis B, pharmaceutical compositions containing thereof, and methods for treatment of hepatitis B. Proposed agent shows the enhanced effectiveness in treatment of hepatitis B.
EFFECT: enhanced and valuable medicinal properties of agent.
83 cl, 6 tbl, 11 ex
SUBSTANCE: method involves carrying out revaccination of children, not reaching the age of 6 years from May to September, next year within the period from May to September.
EFFECT: enhanced effectiveness of revaccination.
FIELD: medicinal plants, chemical technology.
SUBSTANCE: method involves extraction of milled licorice (Glycyrrhiza uralensis, Fischer) roots with 0.5% aqueous solution of NH4OH. The total triterpene acids of extract are precipitated with concentrated H2SO4 followed by extraction of total triterpene acids with 1% solution of H2SO4 in acetone, precipitation of glycyrrhizic acid triammonium salt with 25% solution of NH4OH and its conversion to monoammonium salt by re-crystallization from glacial CH3COOH and purification of the latter by re-crystallization from 85% ethanol. Invention provides enhanced yield of the end product.
EFFECT: improved preparing method, enhanced yield.
1 dwg, 1 ex
FIELD: organic chemistry, medicine, pharmacy.
SUBSTANCE: invention describes derivatives of piperazine of the general formula: or their pharmaceutically acceptable salts wherein Ra - R8a mean phenyl; R8b means pyridyl, or R8 means naphthyl; R1 means hydrogen atom; R2 - R9, R10, R11 mean substituted phenyl; R9, R10, R11 mean substituted pyridyl or pyrimidyl; R9, R10, R11 mean substituted pyridyl-N-oxide or pyrimidyl-N-oxide; R12, R13 mean substituted oxazolyl, naphthyl, fluorenyl, compounds of formulae , or ; R3 means hydrogen atom, (C1-C6)-alkyl, (C1-C6)-alkoxy-(C1-C6)-alkyl, (C3-C10)-cycloalkyl, (C3-C10)-cycloalkyl-(C1-C6)-alkyl; R8 means phenyl; R8 means phenyl-(C1-C6)-alkyl, or R8 means thienyl-(C1-C6)-alkyl; R4, R5, R7 and R13 mean independently hydrogen atom or (C1-C6)-alkyl; R6 means hydrogen atom or (C1-C6)-alkyl; R8 means 1-3 substitutes that mean independently hydrogen atom, halogen atom, (C1-C6)-alkoxyl or -CF3; R8a means 1-3 substitutes that mean independently hydrogen atom, halogen atom, -CF3, -CF3O, -CN; R14 means phenyl, -NHCOCF3 and imidazolyl; R8b means 1-3 substitutes that mean independently hydrogen atom or halogen atom; R9 and R10 mean independently (C1-C6)-alkyl, halogen atom, -NR17R18, -OH, -CF3 and -OCH3; R11 means R9, hydrogen atom, phenyl, -NO2, -CN, -CH2F, -CHF2, -CHO, -CN=NOR17, pyridyl, pyridyl-N-oxide, pyrimidinyl, pyrazinyl, -N(R17)CONR18R19, -NHCONH-(chloro-(C1-C6)-alkyl), -NHCONH-((C3-C10)-cycloalkyl-(C1-C6)-alkyl), -NHCO-(C1-C6)-alkyl, -NHCOCF3, -NHSO2N-((C1-C6)-alkyl)2, -NHSO2-(C1-C6)-alkyl, -N(SO2CF3)2, -NHCO2-(C1-C6)-alkyl, (C3-C10)-cycloalkyl, -SR20, -OSO2-(C1-C6)-alkyl, -SO2CF3, hydroxy-(C1-C6)-alkyl, -CONR17R18, -CON(CH2CH2-O-CH3)2, -OCONH-(C1-C6)-alkyl, -Si(CH3)3 or -B(OC(CH3)2)2; R12 means (C1-C)-alkyl or R14-phenyl; R14 means 1-3 substitutes that mean independently hydrogen, (C1-C6)-alkyl, -CF3, -CO2R17, -CN, (C1-C6)-alkoxyl and halogen atom; R15 and R16 mean independently hydrogen atom and (C1-C6)-alkyl, or R15 and R16 mean in common (C2-C5)-alkylene group and in common with carbon atom to which they are bound form (C3-C6)-spiran ring; R17, R18 and R19 mean independently hydrogen atom or (C1-C6)-alkyl; R20 means (C1-C6)-alkyl. Also, invention describes pharmaceutical compositions containing these compounds and using novel compounds as CCR5 antagonists in treatment of HIV infection, arthritis, asthma, cerebrospinal sclerosis and other diseases.
EFFECT: valuable medicinal properties of compounds and pharmaceutical compositions.
29 cl, 30 tbl, 31 ex
FIELD: chemistry of proteins, virology, pharmacy.
SUBSTANCE: invention relates to novel physiologically active protein conjugates that can be used in medicine. Proposed conjugates is formed by a protein molecule and polyethylene glycol and corresponds to the formula: wherein protein represents interferon α-2b; n and n1 have values providing an average molecular mass of links from about 7500 Da to about 35000 Da. Conjugate shows the enhanced stability as compared with the known analogs. Also, invention relates to a pharmaceutical composition possessing an antiviral activity and containing the indicated conjugate, and to a method for control of viral infection.
EFFECT: valuable medicinal and biological properties of conjugates.
4 cl, 1 dwg, 6 ex
FIELD: medicine, pharmacy, cosmetics.
SUBSTANCE: invention relates to pharmaceutical or cosmetic composition used against insect bites. Proposed composition comprises a soluble salt or mixture of soluble salts of one or some rare-earth elements, triethylene glycol, glycerol, ethyl alcohol, polyethylene oxide, sodium (potassium) hydroxide and purified water. The combination of components taken in the definite ratio provides the creature of pharmaceutical or cosmetic composition preventing itch and topical response in sting of insects. The composition has no biodamaging effect, odor, allergic responses and discomfort state, drying skin effect. The composition can be easily and uniformly distributed on skin being immediately after its applying on skin and without any traces on skin. Proposed compositions can be used for applying on eye regions, lips, mouth cavity and throat mucosa of humans or animals, on regions of insect stings, in particular, mosquito, wasps, gadflies and other insects.
EFFECT: enhanced effectiveness of compositions.
1 tbl, 12 ex
SUBSTANCE: method involves introducing photosensitizer, recording level of its accumulation in tumors, carrying out photodynamic therapy. Pyrogenal is introduced at a dose of 40-1000 mkg/csm2 before introducing photosensitizer into the tumor base with tumor temperature being recorded until stable tumor tissue hyperemia being achieved for 12-24 h. Then, the tumor is smeared with composition containing 3-10 mg of photosensitizer, gel "Ultramix" and 20-200 mcg of Pyrogenal. Treatment with ultrasound is applied with intensity 0.2-0.4 W/cm2, in labile continuous mode within 5-8 min. The composition is left on skin for 1-2 h. Then, photodynamic therapy session is uniformly carried out over the whole tumor area, with total number of 3-5 procedures per treatment course.
EFFECT: enhanced effectiveness of treatment; prolonged optimum photosensitizer dose being supported in tumor, sufficient for effective photodynamic therapy action.
FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a medicinal preparation as a soft medicinal formulation comprising the combination of troxerutin, dexpanthenol, heparin sodium salt, phenylethyl alcohol and special supplements. Gel-forming agent, thickening agent/regulator of acidity and solvent-solubilizing agent are used as the special supplements desirably. Also, invention discloses a method for preparing the novel combined pharmaceutical composition that involves addition of dexpanthenol being preferably as a solution to a mixture of other components and addition if necessary of thickening agent/ regulator of acidity followed by mixing of the mixture to the homogenous state. The novel composition doesn't possess adverse effect and characterized by the high pharmacological activity.
EFFECT: improved and valuable pharmaceutical properties of composition.
17 cl, 1 tbl
FIELD: medicine, cosmetics.
SUBSTANCE: invention proposes a medicinal agent for external using containing the following components: water, polymeric gel-forming composition and fresh donor or slaughter blood of velvet antlers deer in the following ratio of components, wt.-%: rare-cross-linked polymer of acrylic acid or polyvinylpyrrolidone as a gel-forming agent, 1-6; carbomer, 2-7; stabilizing agent, 0.001-0.2; softening agent (glycerol or polyethylene glycol, or propylene glycol), 0.1-30; ethanolamine, up to pH = 6-8; fresh donor or slaughter blood of velvet antlers deer, 0.1-20, and water, the balance. Method for preparing a medicinal agent for external using is based on preparing rare-cross-linked polymer aqueous solution in the ratio water/polymeric gel-forming agent = from 5:1 to 100:1, its mixing with fresh donor or slaughter blood of velvet antlers deer in the ratio = from 1:10 to 10:1 followed by addition of stabilizing and softening agents to prepared solution in the amount from 0.005 to 0.2 wt.-% and from 0.1 to 30 wt.-%, respectively. Prepared solution is stirred and neutralizing agent aqueous solution is added in the amount providing slightly alkaline medium in the final solution. Invention provides simplifying technology providing preparing a highly effective medicinal agent for external using, increasing fitness time up to 2 years being without detriment of its curative properties and reducing consumption for its producing.
EFFECT: improved preparing method, valuable medicinal properties of agent.
FIELD: medicine, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention proposes a preparation used in healing wounds and for prevention sticking a bandage to wound. The preparation comprises hyaluronic acid sodium or potassium salt of molecular mass from 200000 to 2500000 Da, iodine, potassium iodide and water. The preparation is made in form of sterile aqueous solution or gel. The preparation possesses high effectiveness in infected and chronic wounds.
EFFECT: enhanced effectiveness of preparation.
4 cl, 16 dwg, 11 ex
FIELD: medicine, pharmacy, fungicides.
SUBSTANCE: invention relates to a novel pharmaceutical composition as an ointment used in treatment of fungal diseases. Proposed composition comprises 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione as active substance. Ointment comprises solid petroleum paraffin, stearic acid, vaseline oil and emulsion wax as a lipophilic base and benzoic acid as special additive. Pharmaceutical composition is prepared by fusion of solid components of a base followed by addition of 3-methoxycarbonyl-5-(4-chlorobenzylidene)-thiazolidine-2,4-dione concentrate in vaseline oil. Invention provides preparing pharmaceutical composition possessing high chemotherapeutic effectiveness and good tolerance and low toxicity that allows its using in treatment of dermatomycosis of different localization.
EFFECT: valuable medicinal properties of pharmaceutical composition.
2 cl, 2 tbl, 4 ex
FIELD: medicine, gastroenterology.
SUBSTANCE: invention relates to a method for treatment of gastroduodenal ulcers. Method involves carrying out fibrogastroduodenoscopy used for application of gel "APPOLO" containing anilocaine and myramistin on ulcerous defect. The dose of gel is 3-5 ml, course for 3-7 procedures that are carried out every other day. Method provides effect on parasite Helicobacter pylori resulting to accelerated healing ulcerous defects and prolonged arresting the pain syndrome.
EFFECT: improved method of treatment.
FIELD: cosmetics, medicine, pharmacy.
SUBSTANCE: invention relates to compositions used in topical applying and possessing improved water-retaining properties and improved releasing of active agent. Proposed cosmetic compositions contain from 5% to 70% of pentane-1,5-diol by mass and cosmetically acceptable carrier and under condition that this composition doesn't contain polysiloxane, volatile siloxane, phosphatidylcholine, creatine, carnitine, pantenol, pyruvic acid, lauric acid monoglyceride or myristic acid monoglyceride. Also, invention discloses corresponding methods for administration, plaster for attachment of indicated composition to skin and methods for prophylaxis or treatment of skin dryness state or maintaining skin in moisture state. Compositions for topical using and administration of pharmaceutical preparation possess the improved water-retaining properties, improved releasing active agent being without toxicity and skin irritation.
EFFECT: improved and valuable medicinal properties of compositions.
37 cl, 5 tbl, 1 dwg, 6 ex
FIELD: medicine, dermatology, chemical-pharmaceutical industry, pharmacy.
SUBSTANCE: invention relates to a medicament as an ointment formulation used in treatment of hyperkeratosis, ingrown nail and in hygienic treatment of nails deformed as result of trauma and/or aging changes. Proposed agent contains urea, its stabilizing agents, namely a mixture of glycine and aliphatic (C1-C3)-alcohol, and vaseline oil and glycerol as a lipid base and emulsion wax as an emulsifying agent.
EFFECT: valuable medicinal properties of agent.
7 tbl, 1 dwg, 18 ex
FIELD: medicine, in particular topical formulation for treatment of psoriasis and neurodermitis and method for treatment thereof.
SUBSTANCE: the first formulation additionally to naphthalanic ointment comprises oily vitamin A (retinol acetate) 3-4.2 g, oily vitamin E (tocopherol acetate) 3-4.2; Eleuterococcus extract 7-8.3 g, and petrolate. The second formulation additionally to naphthalanic ointment comprises oily vitamin E 3-4.2 g; oily vitamin D 3-4.2; rodiola rosea extract 7-8.3; petrolate. The third formulation additionally to naphthalanic ointment comprises oily vitamin E 3-4.2; oily vitamin A 3-4.2 g; oily vitamin D 3-4.2 peony root extract. Claimed method for psoriasis treatment comprises step 1 (preparative): step 2 (anti-inflammatory); step 3 (prophylaxis). The first treatment step includes medicated treatment using the next drugs: active carbon 1 tablet 3 time per day for 10 days; ketotiphene 1 tablet 1 time per day for 10 days; bellataminal 1 tablet 2 time per day for 10 days, and in parallel - bath with pine extract daily for 10 days. Then dressing with N1 ointment is applied on affected skin areas. Further said step includes administration of cholagogue tea for 10 days and washing of affected skin areas with melilot grass for 15 days. The second step includes administration of anti-inflammatory tea for 30 days followed by administration of bifidum bacterin at 5 doses for 20 days and application of N2 ointment on affected skin areas. The third step includes administration of prophylaxis tea having immunostimulating action for 30 days and application of N3 ointment on affected skin areas, followed by medicated treatment using bellataminal for 30 days - cycloferon intramuscularly 10 injections - Hylac forte for 20 days.
EFFECT: effective complex for psoriasis treatment on any disease stage.
2 cl, 3 ex
FIELD: organic chemistry, pharmacy, pharmacy.
SUBSTANCE: invention relates to novel compounds designated for delivery of active substances to tissues of the following formula: wherein values of radicals R1-R7 are determined in claim 1 of the invention claim, and to their pharmaceutically acceptable salts. Also, invention relates to compositions designated for delivery of active substances to tissues and containing: (A) active substance and (B) at least one compound designated for delivery of active substance to animal tissues of the formula: wherein values of radicals R1-R7 are determined in claims 3-5 of the invention claim. Also, proposed invention relates to a standard medicinal formulation designated for delivery of active substances to body tissues and to a method for preparing indicated compositions and administration of substances for their delivery to body tissues.
EFFECT: valuable properties of compounds.
23 cl, 11 tbl, 11 ex